Jul 2020
SK Biopharmaceuticals Begins Listing on the Korea Exchange
SK Biopharmaceuticals begins listing on the Korea Exchange as the largest market debut of the year. The company plans to increase research and development of commercial and clinical-stage drugs to cure epilepsy, schizophrenia, attention deficit hyperactivity disorder and rare neurological diseases in its bid to address unmet medical needs in the United States.
